Efficacy of metformin monotherapy in US veterans with type 2 diabetes and preexisting chronic kidney disease stage 3.

Aidar R GosmanovDarren E GemoetsLaurence S KaminskyCsaba P KovesdyElvira O Gosmanova

Published in: Diabetes, obesity & metabolism (2021)

Individuals with CKD3 and T2D were at increased risk of metformin monotherapy failure. However, the HbA1c-lowering efficacy of metformin was similar in patients with and without CKD3, highlighting that metformin is a valuable treatment option for newly treated individuals with T2D and CKD3.

Keyphrases

chronic kidney disease
end stage renal disease
combination therapy
open label
randomized controlled trial
smoking cessation